The FDA approved cemdisiran (Livsayis; Regeneron), a subcutaneous siRNA dosed every 3 months, for AChR-positive generalized myasthenia gravis.
In a single-clinic study, 61.5% of patients with psoriasis screened positive for psoriatic arthritis using a validated ...